Amanote Research
Register
Sign In
TCF 7l2 Gene Variant Rs7903146 Affects the Risk of Type 2 Diabetes by Modulating Incretin Secretion
International Journal of Clinical Chemistry and Laboratory Medicine
doi 10.20431/2455-7153.0501002
Full Text
Open PDF
Abstract
Available in
full text
Date
January 1, 2019
Authors
Unknown
Publisher
ARC Publications Pvt Ltd.
Related search
TCF7L2 Variant Rs7903146 Affects the Risk of Type 2 Diabetes by Modulating Incretin Action
Diabetes
Internal Medicine
Endocrinology
Metabolism
Diabetes
Response Letter to Comment On: Villareal Et Al. (2009) TCF7L2 Variant Rs7903146 Affects the Risk of Type 2 Diabetes by Modulating Incretin Action. Diabetes; 59:479-485
Diabetes
Internal Medicine
Endocrinology
Metabolism
Diabetes
Association of Type 2 Diabetes Candidate Polymorphisms in KCNQ1 With Incretin and Insulin Secretion
Diabetes
Internal Medicine
Endocrinology
Metabolism
Diabetes
HLA-DRB1 Reduces the Risk of Type 2 Diabetes Mellitus by Increased Insulin Secretion
Diabetologia
Internal Medicine
Endocrinology
Metabolism
Diabetes
Which Incretin-Based Therapy for Type 2 Diabetes?
The Lancet
Medicine
The Rs738409 (I148M) Variant of the PNPLA3 Gene and Type 2 Diabetes in Yakutia
International Journal of Biomedicine
Erratum: Incretin Mimetics Vie for Slice of Type 2 Diabetes Market
Nature Biotechnology
Applied Microbiology
Biotechnology
Biomedical Engineering
Molecular Medicine
Bioengineering
Comparison of Efficacy Between Incretin-Based Therapies for Type 2 Diabetes Mellitus
BMC Medicine
Medicine
Metabolic Effects of the Incretin Mimetic Exenatide in the Treatment of Type 2 Diabetes
Vascular Health and Risk Management
Pharmacology
Cardiology
Endocrinology
Public Health
Hematology
Environmental
Cardiovascular Medicine
Medicine
Occupational Health
Metabolism
Diabetes
